Home
Home About Us Our Technology News + Media Investor Relations Contact Us
 
Company Press Releases Publications








































































 

Company Press Releases                                                                               Back


Prince William, Duke of Cambridge, Presents Award to CytoSorbents

Wednesday December 10, 2014


Applicatons

Prince William, Duke of Cambridge presents an award to Dr. Phillip Chan, CEO of CytoSorbents Corporation during the Innovation is GREAT Reception at Shutterstock headquarters in the Empire State Building on December 9, 2014 in New York City. The reception was technology themed and the winners of the GREAT Tech Awards were presented with trophies. New York City Mayor Bill De Blasio and British Consul General, New York Danny Lopez also congratulated Dr. Chan and the other winners of the award. CytoSorbents was recognized for its innovative and potentially revolutionary blood purification technology, CytoSorb®, designed to help treat deadly inflammation in patients with life-threatening conditions such as sepsis, trauma, burn injury, lung injury, and others in the intensive care unit.

About CytoSorbents Corporation

CytoSorbents Corporation is a critical care focused immunotherapy company using blood purification to control severe inflammation -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2014, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1910667.

Please Click to Follow us on Facebook and Twitter

Contact:
Company Contact
CytoSorbents, Inc
Dr. Phillip Chan
Chief Executive Officer
(732) 329-8885 ext. *823
pchan@cytosorbents.com
Investor Contact

Amy Vogel
(732) 329-8885 ext. *825
avogel@cytosorbents.com
--------------------------------------------------------------------------------
Source: CytoSorbents Corporation

 
Home | Career Opportunities | Contact Us
© 2014 CytoSorbents Incorporated All Rights Reserved